Medical News

RSS

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.

21 Jul 2010

AB SCIEX and ETH partner to accelerate analysis and improve results for metabolomics

AB SCIEX, a global leader in life science analytical technologies, today announced that it is working with scientists at the ETH Zurich Institute of Molecular Systems Biology as part of the Swiss Systems Biology Program (SystemsX.ch) to accelerate analysis and improve results for metabolomics, which is the scientific study of chemical processes involving metabolites.

21 Jul 2010

Pharmarama ranked as Britain's 8th fastest-growing private company for overseas sales

Pharmarama International, a leader in strategically sourcing comparator medicines for clinical trials worldwide, today announced that it has been ranked as Britain's eighth fastest-growing private company for overseas sales in a 2010 survey published by the country's leading business newspaper, The Sunday Times.

21 Jul 2010

New insights on early pathogenic events, strategies for preventing HIV infection

In a plenary lecture at the 18th International AIDS conference in Vienna, Austria, Anthony S. Fauci, M.D., will present new insights on the early and complex pathogenic events that occur rapidly-within hours to days-following sexual exposure to HIV.

21 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

Report: Older gay, bisexual men enrolled in long-term study of HIV used illicit drugs infrequently

Most older gay and bisexual men enrolled in a long-term study of HIV used recreational drugs infrequently over a 10-year period, report University of Pittsburgh Graduate School of Public Health researchers at the XVIII International AIDS Conference.

21 Jul 2010

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.

21 Jul 2010

Researchers develop new way to reduce radiation dose in CT perfusion procedure

Perfusion CT scanning, an emerging imaging technology, got a bad rap last year when a machine set to incorrect radiation levels overdosed hundreds of people in Los Angeles. In the wake of this incident, researchers at the Mayo Clinic, excited by the technology's promise for diagnosing stroke, cancer, and possibly heart disease, have developed a way to reduce the amount of radiation involved in the procedure -- which, when done properly, already involves very little risk.

21 Jul 2010

Quest Diagnostics income from continuing operations increases to $195 million in second-quarter 2010

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations increased to $195 million, or $1.07 per diluted share, compared to $188 million, or $1.00 per diluted share, in the second quarter of 2009. Results for 2009 included a benefit associated with an insurance recovery of $0.05 per share, offset by charges of $0.04 per share associated with the company's debt repurchase and an investment writeoff.

From Quest Diagnostics 21 Jul 2010

Concentric Medical announces treatment of first stroke patient with Merci Retriever

Concentric Medical, Inc., the global leader in devices for clot removal in acute ischemic stroke patients, today announced the treatment of the first patient in Japan with the Merci Retriever. The Merci Retriever is a catheter-based medical device that stroke centers use to remove blood clots from the brains of patients suffering an acute ischemic stroke.

21 Jul 2010

Burger King to offer breakfast meal that meets BKC's stringent nutrition criteria

Today Burger King Corp. announced it will offer a breakfast meal for children that meets BKC's stringent nutrition criteria for advertised Kids Meals, as defined in its pledge through the Council of Better Business Bureau's Children's Food and Beverage Advertising Initiative.

21 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Abbott today announced financial results for the second quarter ended June 30, 2010.

21 Jul 2010

Cara Therapeutics closes Series D financing of $15 million

Cara Therapeutics, Inc. announced today that it had closed on a Series D financing of $15 million. The round was led by new investor, Rho Ventures, with participation from previous investors Alta Biopharma, Ascent Biomedical Ventures, CT Innovations, Devon Park BioVentures, Healthcare Private Equity, Mitsubishi International Corporation and MVM Life Science Partners.

21 Jul 2010

First Edition: July 21, 2010

Today's headlines include news regarding specific examples of what could happen at the state level if Congress doesn't extend enhanced federal Medicaid funding.

21 Jul 2010

CAP calls for increased FDA oversight of laboratory developed and 'direct-to-consumer' tests

With the increasing importance of laboratory tests in diagnosing and treating disease, representatives of the College of American Pathologists (CAP) today presented recommendations to the Food and Drug Administration (FDA) urging increased oversight of laboratory developed tests (LDTs) and "direct-to-consumer" tests. Most genetic tests fall into one or both of these testing categories.

21 Jul 2010

Jericho Systems selected to provide key components of NHIN

Jericho Systems Corporation, a leader in distributed enterprise identity and access management solutions for evolving SOA environments, is one of only eight civilian companies selected to provide key components of the new Nationwide Health Information Network that facilitates the exchange of clinical data between the Department of Defense, Veterans Administration, and private healthcare providers.

21 Jul 2010

Target Health, LifeOnKey partner to offer web-based information platform to optimize clinical trials

Target Health Inc. and LifeOnKey, Inc. today announced they have joined forces to offer an innovative, web-based information platform that will allow the bio-pharmaceutical and medical device industries to optimize clinical trials, help researchers capture, analyze and assess trial data more efficiently, and bring innovative new medicines and devices to patients.

21 Jul 2010

Medical News

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

AB SCIEX and ETH partner to accelerate analysis and improve results for metabolomics

Pharmarama ranked as Britain's 8th fastest-growing private company for overseas sales

New insights on early pathogenic events, strategies for preventing HIV infection

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

Report: Older gay, bisexual men enrolled in long-term study of HIV used illicit drugs infrequently

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

Researchers develop new way to reduce radiation dose in CT perfusion procedure

Quest Diagnostics income from continuing operations increases to $195 million in second-quarter 2010

Concentric Medical announces treatment of first stroke patient with Merci Retriever

Burger King to offer breakfast meal that meets BKC's stringent nutrition criteria

Health Canada grants Osiris Priority Review for Prochymal NDS

Researchers find that increase in leptin may promote colorectal neoplasms

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Cara Therapeutics closes Series D financing of $15 million

First Edition: July 21, 2010

CAP calls for increased FDA oversight of laboratory developed and 'direct-to-consumer' tests

Jericho Systems selected to provide key components of NHIN

Target Health, LifeOnKey partner to offer web-based information platform to optimize clinical trials

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News